12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Certriad rosuvastatin/fenofibric acid: Development discontinued

AstraZeneca and Abbott discontinued development of dyslipidemia candidate Certriad. The companies made the decision after reviewing a March complete response letter and determining that further development...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >